Participate in IBD Research!

 

8/1/2016 – I’m sorry but this study

has closed.

However, you can still participate

in finding out All About YOU!

by getting your 23andMe DNA tests done.

 

Click here for further info.

 

 

 

 

Want to Participate in IBD Research?

 

Ground Breaking Research!

 

You Could Change the Future of IBD.

Join 10,000 participants with IBD, and participate in IBD Research!

 

 

Do You Want To Change the IBD World?                     Then Become Active in Upcoming Research!!!       It May One Day Change Your Very Own IBD, UC, or Crohn’s Prognosis!

 

 

 

 

 

 

Want to Participate in IBD Research?

 

 

We’re excited to share an opportunity to

help change the future of Inflammatory

Bowel Disease (IBD),UC, Crohn’s.

 

 

In collaboration with, 23andMe , they’ve launched a

new research initiative to study the genetic factors

 around IBD, a condition that affects millions.

 

 

Please join ( at no cost to you) our IBD Research
Initiative recruitment campaign,

Want to Participate in IBD Research?

 

Click here for details.

Genetics and IBD, UC, Crohn’s.

 

“…At 23andMe, we believe genetic data plays a critical role in research. Knowing more about how genetics relate to a disease can provide additional information on how people might respond to treatments,  which may eventually lead to a cure.

Today, there are very few medications for IBD.
Maintaining the quality of daily life can be a challenge.


It is not known which medications will be effective
on individuals and some IBD medications stop working over time.

There is very little those diagnosed with IBD can do and often times, surgery becomes the only
solution available.

 

We believe DNA may play a critical role in IBD treatment. Genetics has started playing a larger role in medicine over the past few years. And genetics could provide insight as to why some people are more likely to get IBD and why people respond differently to treatment
options and drugs…”

 

What makes this different.

1) You can participate without leaving your home.
2) Your participation takes fifteen minutes.
3) And your participation is anonymous.

4) Traditional research studies may involve
out-of-home blood tests, visits to clinics,
nurse practitioner calls, local research
facility visits and even drug trials. And,
if you don’t live close to a research facility,
you may not even have the opportunity to participate. Geography alone can slow down
research and ultimately, better treatment.

23andMe believes everyone who wants to
participate in research should be able to
participate in research.

Participate without leaving your home and, it takes just fifteen minutes.

With this study you complete a
15-minute online survey
and provide a saliva sample.

And finally, what also makes us
different is your ability
to participate in future IBD
studies around the world.
Your information will go into more IBD studies
after our first partnership with Pfizer.
We believe researchers and scientists
around the world should have access to
information, which can lead to, and
accelerate, better treatment.

 

Your participation.

If you are eligible to participate, we will send you
a 23andMe DNA-saliva kit at no cost.
We will ask you to answer a short online
survey (15 minutes) about your personal
IBD journey, symptoms, response to
treatments, etc. Your privacy is important to us and participation is anonymous.

Click here for details.

          Participation is Anonymous

Benefits for participants.

  • You will receive access to 23andMe’s PersonalGenomeService® (valued at $99)
  • You will learn about your genetic ancestry.
  • You will have access to your uninterpreted genetic data.

 

 

“…Our promise to you.

We promise quarterly updates on our recruiting
progress and promise to answer questions
you may have throughout the study. As we grow
our participant base and analyze the data,
there may be additional opportunities to participate
in surveys. If you would like to continue your
participation, you will have the opportunity to provide
ongoing contributions. We will communicate
any additional survey opportunities in the quarterly
updates and in your 23andMe.com profile dashboard.

Click here for details.

See if you’re eligible.

IBD is a group of inflammatory conditions of the colon
and small intestine. People who have been diagnosed
with Crohn’s disease or ulcerative colitis are eligible
for this study.

In order to participate in the first study within the IBD
community, you must meet all six criteria below:

  1. You’ve been diagnosed with Crohn’s disease or ulcerative colitis by a qualified physician.
  2. You’re willing to submit a saliva sample for DNA testing and complete online surveys related to your condition.
  3. You have access to the internet.
  4. You are at least 6 years old (minors under 18 require parental consent to enroll).
  5. You are not a 23andMe customer.
  6. You reside in the United States.

If you are a current 23andMe customer, learn how you can participate here.

 

“…Our scientific advisors.

We believe IBD experts from around the world can help
play a critical role in our IBD research community.

We’ve selected five advisors with a range of IBD expertise
globally. They are not part of 23andMe or Pfizer
(or any other study partner). They are experts in the
IBD field and their experience can range from
seeing patients to being a part of cutting edge research.
They assist us with survey development, data analysis and help guide our research so our goals are unbiased, not self-serving.

One of our research advisors, Dr. Smarr, suffers from IBD
which fuels his drive to search for a better treatment.

  • Dermot McGovern, MD, Ph.D, FRCP, is Director of Translational Medicine and Professor of Medicine at Cedars-Sinai Medical Center in Los Angeles. Dr McGovern is the Endowed Chair in Inflammatory Bowel Disease (IBD) Genetics and serves on the Steering Committee of the NIDDK IBD Genetics Consortium, the Management Committee of the International IBD Genetics Consortium, and the National Scientific Advisory Board of the Crohn’s and Colitis Foundation of America (CCFA). Dr McGovern completed his clinical training with a focus on Crohn’s disease and ulcerative colitis in Oxford, UK and holds a doctorate from the University of Oxford on IBD Genetics. Dr McGovern’s research has been instrumental in identifying many of the known IBD genes and as an IBD clinician he is particularly interested in translating these genetic findings to the clinic through the development of models that predict disease behavior and response to therapy as well as identifying new areas for the development of treatments for both Crohn’s disease and ulcerative colitis.
  • Nir Modiano, MD, Ph.D, is Board Certified in Internal Medicine and Gastroenterology and serves as Director of the Inflammatory Bowel Disease Program at Oregon Health and Science University, where he is an assistant Professor of Medicine in the Division of Gastroenterology and Hepatology. He obtained a Bachelor’s degree, advanced graduate training in Immunology, and his medical degree at Yale. He then completed his Residency in Internal Medicine at Stanford University, his Gastroenterology Fellowship at UCLA, and his advanced Fellowship training in IBD at Cedars-Sinai Medical Center. His interest in the cultural dimensions of patient care has led him to work at a hospital in Botswana, Africa and in the Indian Health Service as part of his training, and to lead a course on The Healer’s Art. His scientific experience spans molecular, clinical, and genetic research modalities, and his recent research interests include identifying genetic subtypes of Crohn’s disease and investigating new treatment and diagnostic modalities in Crohn’s disease and Ulcerative Colitis.
  • William Sandborn, MD, completed medical school and an internal medicine residency at Loma Linda University in Loma Linda California. He completed a gastroenterology fellowship at the Mayo Clinic in Rochester Minnesota in 1993. From 1993-2010, he was on the faculty of the Mayo Clinic, rising to Professor of Medicine, Vice Chairman of the Division of Gastroenterology and Hepatology, and Associate Dean of Research for Intellectual Property and Industry Relations. In 2011 he became Professor of Clinical Medicine at the University of California San Diego and Director of the IBD Center and Chief of the Division of Gastroenterology for the UC San Diego Health System. Dr. Sandborn has published over 444 peer reviewed articles including articles in the New England Journal of Medicine, the Lancet, JAMA, the Annals of Internal Medicine, and Gastroenterology. His research interests are clinical trials and clinical pharmacology related to inflammatory bowel disease.
  • Larry Smarr, Ph.D, is the founding Director of Calit2, the California Institute for Telecommunications and Information Technology (a UC San Diego/UC Irvine partnership,) and holds the Harry E. Gruber professorship in the Department of Computer Science and Engineering (CSE) of UCSD’s Jacobs School of Engineering. He is a member of the National Academy of Engineering, as well as a Fellow of the American Physical Society and the American Academy of Arts and Sciences. In 2006 he received the IEEE Computer Society Tsutomu Kanai Award for his lifetime achievements in distributed computing systems. He serves on the NASA Advisory Council to the NASA Administrator, the DOE ESnet Policy Board, and chairs the NSF Advisory Committee on Cyberinfrastructure. For 8 years he was a member of the NIH Advisory Committee to the NIH Director, serving 3 directors. He served as PI of the NSF OptIPuter project and for the last 7 years he has been the PI of the Moore Foundation CAMERA global microbial metagenomics computational repository. You can follow him at https://lsmarr.calit2.net

 



Click here for details.

 

 

What do I think about this?

I see our participation in the IBD Research as a great opportunity
to impact the future of IBD, UC, and Crohn’s.

And since it’s at no cost to you, it’s really a win-win for all.


I’m joining, what about you?

Click here for details.

Comments are closed.